Toray Of Japan, Kyoto University Develop Patient-Specific Breast-Cancer Test
This article was originally published in PharmAsia News
Japan’s Toray Industries has joined with Kyoto University to develop a test to determine if Genentech’s Herceptin (trastuzumab) for treating breast cancer would be an effective treatment for certain patients.
You may also be interested in...
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.